Urinary Biomarkers for Lung Cancer Detection

Alexandre Matov[1, †]

[1] DataSet Analysis LLC, 155 Jackson St, San Francisco, CA 94111

[†] Corresponding author:

email: matov@datasetanalysis.com

Key words: Small RNA, Longitudinal Analysis, Disease Detection, Early Disease

ABSTRACT

Introduction: The current healthcare system relies largely on a passive approach toward disease detection, which typically involves patients presenting a "chief complaint" linked to a particular set of symptoms for diagnosis. Since all degenerative diseases occur slowly and initiate as changes in the regulation of individual cells within our organs and tissues, it is inevitable that with the current approach to medical care we are bound to discover some illnesses at a point in time when the damage is irreversible and meaningful treatments are no longer available.

Methods: There exist organ-specific sets (or panels) of nucleic acids, such as microRNAs (miRNAs or miRs), which regulate and help to ensure the proper function of each of our organs and tissues. Thus, dynamic readout of their relative abundance can serve as a means to facilitate real-time health monitoring. With the advent and mass utilization of next-generation sequencing (NGS), such a proactive approach is currently feasible. Because of the computational complexity of customized analyses of "big data", dedicated efforts to extract reliable information from longitudinal datasets is key to successful early detection of disease.

Results: Here, we present our preliminary results for the analysis of healthy donor samples and drug-naïve lung cancer patients.

INTRODUCTION

The cancer incidences and mortality rates worldwide demonstrate that for some cancers, such as lung, stomach, liver, esophagus, leukemia and pancreas cancer, the diagnosis is almost inevitably linked to a loss of life. The 5-years survival rate for patients with lung cancer, the "biggest killer", is 47% for stage I and can be as low as 2% for stage IV, which underscores the importance of early detection (World Health Organization, 2017). Methods for the early detection of disease based on the analysis of body fluids have

become popular, however, the identification of biomarkers in urine is one of the few non-invasive approaches. There are approximately two thousand miRNAs that have been identified in the literature (Kozomara and Griffiths-Jones, 2014) and catalogued in the miRBase database (Kozomara and Griffiths-Jones, 2014). Most of these miRNAs have been associated with the function of specific human organs and tissues, and the dysregulation of many of them has been linked to cancers (Di Leva et al., 2014; Hayes et al., 2014), cardiovascular diseases (Wojciechowska et al., 2017), neurological disorders (Quinlan et al., 2017) and other degenerative diseases. It has also been demonstrated that it is possible to discriminate between healthy individuals of different ages as well as between the two sexes based on the analysis of miRNAs isolated in urine samples (Ben-Dov et al., 2016). This work determined that the intra-individual variability is considerably smaller than inter-individual differences, which is important in the context of longitudinal analysis of healthy samples, and that the exact timing of urine collection minimally affects the urine miRNA transcriptome. Therefore, our hypothesis is that longitudinal changes in miRNA transcriptomes can be used to detect disease onset before manifestation of any symptoms. As a concrete preliminary analysis of disease-specific changes, we have chosen to highlight the specific case of lung cancer.

Approximately 190 miRNAs (Aushev et al., 2013; Backes et al., 2016; Bianchi et al., 2011; Boeri et al., 2012; Boeri et al., 2011; Cazzoli et al., 2013; Chen et al., 2012; Geng et al., 2014; Leidinger et al., 2014; Leidinger et al., 2016; Li et al., 2015; Markou et al., 2016; Nadal et al., 2015; Nadal et al., 2014; Qu et al., 2017; Wang et al., 2014; Wozniak et al., 2015; Yan et al., 2014; Zhou et al., 2017; Zhu et al., 2016) have been linked to lung cancer based on transcriptomic data of specimens derived from primary tumors and/or blood. The top 19 most common markers have been identified in at least three independent screens and some are listed in as many as six or more, suggesting that they are disease markers of high fidelity. The fidelity of markers will also be based on whether they have been identified in both the primary tumors and in blood samples as well as the impact factor of the journal in which the results are published. We will

start the health monitoring of lung cancer by accumulating statistics on these 190 markers with a special emphasis on the top 19 most established ones. In addition to establishing this miRNA biomarker panel for lung cancer, we have also identified similar but smaller (i.e., based on fewer established blood biomarkers) panels for colorectal and prostate cancer (in males); breast, uterus, cervical, and colorectal cancer (in females); as wells as urinary pancreatic cancer biomarkers (Debernardi et al., 2015). The necessity to consider different sets of biomarkers for males and females, depending on age will be discussed in the next section. The biomarker lists will be updated as new literature becomes available and whenever our own work allows for the identification of novel markers.

The treatment of lung cancer is often hampered by late diagnosis (Del Ciello et al., 2017; Ellis and Vandermeer, 2011; Polanski et al., 2016). When discovered early, the disease is curable via surgical intervention as adenocarcinoma nodules can simply be resected (Lackey and Donington, 2013). For patients with locally advanced or metastatic disease, multiple drug treatment options are offered yet there are rarely curative regimens available (Socinski et al., 2018). Immunotherapy seems to be a promising approach for a curative therapy (Rizvi et al., 2015), but it too has its limitations as there are very few patients who respond to it and the associated toxicity is of considerable concern (Carbone et al., 2017). While current research efforts in the area of drug development have focused on identifying biomarkers for immunotherapy susceptibility (Ayers et al., 2017; Cristescu et al., 2018; Gettinger et al., 2018), our approach to improving the standard of care in lung cancer treatment is to identify biomarkers for early detection of the disease when curative surgery is still a viable option.

Our expectation is that this health monitoring service will alert the participants of the emergence of a particular disease, create the impetus to discuss this alert with her/his physician, and ultimately take appropriate prophylactic action, e.g., to make lifestyle changes or to elect to undergo early treatment. Our central hypothesis is that urinary biomarker panels could serve as personalized health monitoring readouts

by virtue of periodic measurements. Furthermore, we hypothesize that gradual changes in urinary nucleic acids will indicate the onset of disease by changes compared to a baseline healthy state that could reveal the type of disease by exhibiting changes in specific biomarkers for each disease. Ultimately, this approach will allow for overall health monitoring and early detection of the onset of any disease, and might also allow for screening for other deviant processes such as physiological disorders.

MATERIALS AND METHODS

Body Fluids Biobank

To begin to build a repository of patient samples, we will ask participants to contribute body fluids samples (which will be stored in a biobank) and to complete health-related questionnaires every three months. This specific sampling interval is selected because it corresponds to the longest time interval during which new disease can be expected to remain at surgically resectable levels (Quint, 2003). 250 ml of urine void will be collected in a tube containing Norgen Biotek Corp. preservative. Time and date of collection will be logged on a urine worksheet by the laboratory, and the sheet will remain in the tube. Urine appearance will be noted in the log file as “Clear”, “Turbid”, “Yellow” or “Brown”. Before long term storage, the 250 ml collection tube will be centrifuged for 20 min at 4 C at 500 g and the supernatant aliquoted in five 50 ml tubes (the sediment pellet containing epithelial cells will be discarded). For each participant, during each collection, 250 ml of urine void will be aliquoted in five 50 ml falcon tubes for long term storage at -20 C.

Sample Processing

Small RNA were extracted from de-identified urine samples by Norgen Biotek Corp. Our primary methodology is to collect body fluids for analysis. To perform research and identify biomarkers for early detection of disease, every three months we collect body fluids and store them at negative temperatures with the objective to perform genetic sequencing and statistical analyses of longitudinal data. The urine

voids are collected via specialized urine container 250 ml cups custom-manufactured by Norgen Biotek Corp. which are shipped at room temperature.

During the initial data-aggregation phase when we will rely on a medical diagnosis to establish an endpoint, each participant will be expected to provide information from their general practitioner in regard to the type of diagnosed disease. We anticipate this initial stage to last about two to three years during which 7% of the participants of age 45 to 75 are expected to develop a degenerative disease. During this stage our focus will be on identifying biomarkers for early disease detection. If we assume ten thousand participants, based on statistics obtained from hospitals (personal communication), within two years 695 participants will develop degenerative diseases of which roughly 220 participants will be diagnosed with a cancer, 436 participants will be diagnosed with a cardiovascular disease and 39 participants will develop a neurological disorder.

The longitudinal datasets with a disease diagnosis endpoint will allow for the discovery of biomarkers for early detection. Furthermore, the continued collection of samples from these participants will allow for accumulation of datasets for the evaluation of drug efficacy and provide prognostic and predictive value. In the long run, this will empower those participants who develop disease by providing additional information to their treating physicians. The remaining participants (93%) providing healthy samples will continue participation beyond the initial phase of two years and, once early disease biomarkers are discovered and validated, will be offered the chance to participate in our phase two health monitoring service.

Data Analysis

All data analysis programs and graphical representation of the results were developed in R and Matlab. The computer code is available for download at: https://github.com/amatov/DiseaseDetectionUrine. To

obtain preliminary data, we used the computational topology software (Perseus (Tyanova and Cox, 2018)) to analyze longitudinal data of 15 healthy donors taken every two months for three different time points. PCA analysis grouped data points of the same individuals together in triplets, which was an expected result, but we were also able to detect trends in how the values for every individual change with time (see Results). This illustrates the transient nature of the miRNAs levels and the importance of understanding normal biological noise / fluctuations in miRNA levels across the lifespan of healthy individuals.

We also aimed at discovering population-based panels of biomarkers. The small sizes of our preliminary datasets preclude utilization of standard methods, e.g., differential expression analysis (Robinson et al., 2010), so we opted to perform information theory-based computation to identify biomarkers. As the size of our datasets increases, so will our ability to make meaningful biomarker identifications. For the selection of disease-specific panels, several approaches are available for feature selection, for instance, by maximization of mutual information (Jiao et al., 2015) or applying the "maximum of the minimum criterion" (Bennasar M., 2015). The preliminary methodology we utilized for computation of relative entropy via Kullback-Leibler (KL) divergence is based on an adaptive minimax rate-optimal estimator (Han et al., 2016) of the changes in disease from healthy state(s) to cancerous lesion(s) and malignant tumor(s). Consider the KL divergence as:

$$D(P||Q) \triangleq \begin{cases} \sum_{i=1}^{S} p_i ln \frac{p_i}{q_i} & if\ P \ll Q, \\ +\infty & \text{otherwise}, \end{cases} \qquad (1)$$

where two patient cohorts are considered, $P = \{p_1, \dots, p_s\}$ and $Q = \{q_1, \dots, q_s\}$, over a common set of miRNAs of length S (S=947 miRNAs for this dataset). Testing this approach for significant feature selections on a small cohort of 13 stage IV lung cancer patients' urine samples, we selected miRNAs by computing Eq. (1) (see Results).

RESULTS

Nucleic Acids Biomarkers

At least 1,917 human miRNAs have been described in the literature (Kozomara and Griffiths-Jones, 2014), and we have detected 947 of them in urine. The levels of miRNA change as a function of age and systematic differences exist between the two sexes (Ben-Dov et al., 2016). There are three main categories of degenerative diseases - cardiovascular (e.g., hypertension, coronary disease, myocardial infarction), neoplastic (tumors and cancers), and nervous system-related (e.g., Alzheimer's disease and Parkinson's disease). The etiology of these diseases typically involves some combination of aging and poor lifestyle choices. It is, therefore, conceivable that the collection and analysis of urinary miRNA panels longitudinally would allow to delineate changes in physiology associated with a particular disease in its early (asymptomatic) stage.

Figure 1 shows an example of the miRNAs detection in the urine of a healthy individual. Not all of the miRNAs we detected in urine are present in all subjects for each of the time points. We aimed at discovering personalized biomarker panels, which would allow anyone to make informed decisions and alert about the need for lifestyle changes or to seek medical advice. In this context, we sought to identify meaningful patterns and predictive trends in miRNA levels present in patient urine and blood specimens.

Biomarker Panels in the Literature

First, we performed a literature search and identified a panel of 25 high fidelity lung cancer biomarkers, based on miRNAs each previously linked to lung cancer development, progression and drug resistance in multiple (between three and eight) papers on the analyses of blood of lung cancer patients and primary lung tumors (Aushev et al., 2013; Backes et al., 2016; Bianchi et al., 2011; Boeri et al., 2012; Boeri et al., 2011; Cazzoli et al., 2013; Chen et al., 2012; Geng et al., 2014; Leidinger et al., 2014; Leidinger et al., 2016; Li et al., 2015; Markou et al., 2016; Nadal et al., 2015; Nadal et al., 2014; Qu et al., 2017; Wang et



Figure 1. Expression levels (logarithmic scale) of 947 miRNAs sequenced by NGS from urine samples for one of the 15 healthy individuals over three time points. Example of visualization of urine data based on 947 miRNAs plotted on the X-axis versus miRNA expression levels (in arbitrary units) as plotted on the Y-axis. Time point 1 levels are displayed in red, time point 2 levels are displayed in blue and time point 3 levels are displayed in green.

al., 2014; Wozniak et al., 2015; Yan et al., 2014; Zhou et al., 2017; Zhu et al., 2016). Lung cancer is the leading cause of cancer-related deaths and claims more lives each year than all other major cancers combined. Lung cancers are generally diagnosed at an advanced stage because patients lack symptoms in the early stages of the disease. We measured an increase in the levels of 16 of these 25 miRNAs for one of the healthy individuals in our baseline cohort (Fig. 2). The most commonly published biomarkers of lung cancer, which we found to have an increase longitudinally are miRNA-21-3p, miRNA-140-3p and miRNA-93-3p. We did not consider those miRNAs for which there have been reports in the literature of a downregulation in disease, because their levels might appear decreased in urine for other physiological reasons than cancers.

Computational Analysis

After establishing that it was feasible to identify published cancer miRNAs in urine, we sought to investigate whether healthy donors retain similar patterns in their miRNA profiles longitudinally via PCA



Figure 2. Longitudinal changes of lung cancer-related urinary miRNAs in a healthy individual. An example of up-regulation of 16 urinary biomarkers within a panel of 25 high fidelity lung cancer biomarkers, based on miRNAs each previously linked to lung cancer development, progression and drug resistance in multiple (between three and eight) papers on the analyses of blood of lung cancer patients and primary lung tumors. X-axis, list of the biomarkers: from left to right: (1) miRNA-21-3p, (2) miRNA-21-5p, (3) miRNA-140-3p, (4) miRNA-140-5p, (5) miRNA-155, (6) miRNA-200b-3p, (7) miRNA-200b-5p, (8) miRNA-223-3p, (9) miRNA-223-5p, (10) miRNA-221-3p, (11) miRNA-221-5p, (12) miRNA-145-3p, (13) miRNA-145-5p, (14) miRNA-150-3p, (15) miRNA-150-5p, (16) miRNA-200a-3p, (17) miRNA-200a-5p, (18) miRNA-205-3p, (19) miRNA-205-5p, (20) miRNA-210-3p, (21) miRNA-210-5p, (22) miRNA-339-3p, (23) miRNA-339-5p, (24) miRNA-93-3p, (25) miRNA-93-5p. Y-axis, abundance levels; we performed data normalization using the quantile normalization method recommended for next-generation sequencing data based on single color experiments.

(Fig. 3). To this end, we processed samples of 15 healthy individuals collected every two months for three time points, i.e., 45 samples in total. This analysis showed that even if there is a certain level of variability, (i) each three longitudinal samples from the same healthy individual cluster together - at least for two of the three time points - and (ii) the longitudinal sample triplets for each of the different healthy individuals form separate clusters (see on Fig. 3 sample triplets per individual color-coded in the same color – pink for donor #1, red for donor #2, cyan for donor #3, blue for donor #4, brown for donor #5, yellow for donor #6, orange for donor #7, etc.). This demonstrates that, in normal physiology, urinary miRNA panels can identify the same person longitudinally.

One of our aims has been to discover personalized disease-specific miRNAs biomarker panels based on significant changes in organ or tissue regulation in disease. As a first step in this regard, we aimed at discovering population-based panels of biomarkers. The preliminary methodology we utilized for computation of relative entropy via Kullback-Leibler (KL) divergence is based on an adaptive minimax rate-optimal estimator (Han et al., 2016) of the changes in disease from healthy state(s) to cancerous lesion(s) and malignant tumor(s). We set our threshold at 1.2 bits divergence empirically and this allowed us to identify 20 biomarkers discriminative of lung cancer (Fig. 4). All 20 biomarkers have previously been published in the literature on lung cancer based on analyses of primary lung tumors and blood from



Figure 3. Longitudinal analysis of 45 samples from 15 healthy donors; X-axis Component 1 (21.4%), Y-axis Component 2 (13.1%). PCA analysis of longitudinal data of healthy donors taken at three different time points demonstrates the transient nature of the miRNAs levels. The panel consists of 15 healthy donors which provided void urine samples in the Netherlands. Each triplet 1-2-3 in the same color on the PCA scatter plot belong to the same healthy individual over three time points. The time step at which these samples were collected and sequenced was two months. One of the triplets is labeled 2-3-4 because the first sample was not processed correctly and that required the collection of another one at a later, fourth, time point.

lung cancer patients (Bao et al., 2018; Wan and Zheng, 2021; Wang et al., 2014). This selection demonstrates the suitability and ability of this method for the identification and selection of disease-specific biomarkers. Even if this computation is based on small sample cohorts and it is not patient-specific, it indicates the possibility to detect lung cancer in urine samples. Our objective will be to provide every individual with the option to make data-driven decisions in the context of the prevention of the progression of degenerative diseases.



c

Figure 4. Kullback-Leibler divergence between drug-naïve lung cancer patients and healthy individuals. miRNAs levels in a cohort of 28 participants (13 stage IV drug-naïve lung cancer patients and 15 healthy individuals) allowed for the selection of a panel of 20 discriminative biomarkers out of 947 detected by next-generation sequencing in urine samples: (1) miRNA-891a-5p, (2) miRNA-196a-5p, (3) miRNA-200a-5p, (4) miRNA-577, (5) miRNA-141-3p, (6) miRNA-29c-3p, (7) miRNA-95-3p, (8) miRNA-29b-3p, (9) miRNA-361-5p, (10) miRNA-429, (11) miRNA-335-5p, (12) miRNA-421, (13) miRNA-628-3p, (14) miRNA-660-5p, (15) miRNA-29a-3p, (16) miRNA-4454, (17) miRNA-330-3p, (18) miRNA-194-5p, (19) miRNA-532-3p, (20) miRNA-1271-5p. All 20 biomarkers have previously been published in the literature on lung cancer based on analyses of primary lung tumors and blood from lung cancer patients.

DISCUSSION

The cancer incidences and mortality rates worldwide demonstrate that for some cancers, such as lung, stomach, liver, esophagus, leukemia and pancreas cancer, the early diagnosis is of critical importance. We

will develop algorithmic solutions to facilitate the longitudinal analyses of transcriptomic miRNA data from tens of thousands of patients (about 1,917 miRNAs have been described in the literature and we have detected 947 of them in urine) and the early detection of disease. To achieve this end, we will use multivariate data and multi-dimensional clustering analyses as well as information theory approaches based, for instance, on entropy computation and feature selection using joint mutual information maximization. Our overall objective is to significantly improve the quality of life in the last three to four decades of living.

The methodology we propose may allow the development of molecular diagnostics tests based on nucleic acid markers for monitoring of cardiovascular, neoplastic, and diseases of the nervous system based on the longitudinal analyses of body fluids. Further, the approach may provide novel ways for treatment evaluation. Correlation between changes in biomarker levels and treatment responses will allow for the early detection of a lack of response after treatment and ultimately for optimal drug selection. It will also facilitate the discovery of biomarkers for the prediction of disease relapse. In the long run, longitudinal analysis of nucleic acids will allow for the development of novel targeted drugs. Recent literature has described many examples of miRNAs that could be targeted in disease (Duygu et al., 2016; Kim et al., 2017; Singh and Sen, 2017). Therefore, monitoring of their levels in healthy individuals and patients undergoing disease treatment will likely provide valuable datasets for the pharmaceutical industry as well as for practicing physicians, ultimately allowing them to select the most efficacious treatment sequence and drug combination for each patient.

Ethics Declaration

IRB (IRCM-2019-201, IRB DS-NA-001) of the Institute of Regenerative and Cellular Medicine.

Ethical approval was given.

Funding

No funding.

ACKNOWLEDGEMENTS

I thank JR&D Services, Rotterdam for funding in the context of NGS data. I am grateful to the Institute of Regenerative and Cellular Medicine, Santa Monica for issuing the Institutional Review Board protocol approval IRCM-2019-201, IRB DS-NA-001 for the observational study "Longitudinal analysis of next-generation sequencing of nucleic acids for early detection of degenerative diseases such as cardiovascular, neoplastic and diseases related to the nervous system" and James Faber for his feedback regarding the protocol and the process of approval.

REFERENCES

World Health Organization. 2017. Global yearly cancer incidence and mortality. *World Health Organization and the American Cancer Society*.

Aushev, V.N., I.B. Zborovskaya, K.K. Laktionov, N. Girard, M.P. Cros, Z. Herceg, and V. Krutovskikh. 2013. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. *PloS one*. 8:e78649.

Ayers, M., J. Lunceford, M. Nebozhyn, E. Murphy, A. Loboda, D.R. Kaufman, A. Albright, J.D. Cheng, S.P. Kang, V. Shankaran, S.A. Piha-Paul, J. Yearley, T.Y. Seiwert, A. Ribas, and T.K. McClanahan. 2017. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. *The Journal of clinical investigation*. 127:2930-2940.

Backes, C., N. Ludwig, P. Leidinger, H. Huwer, S. Tenzer, T. Fehlmann, A. Franke, E. Meese, H.P. Lenhof, and A. Keller. 2016. Paired proteomics, transcriptomics and miRNomics in non-small cell lung cancers: known and novel signaling cascades. *Oncotarget*. 7:71514-71525.

Bao, M., S. Pan, W. Yang, S. Chen, Y. Shan, and H. Shi. 2018. Serum miR-10a-5p and miR-196a-5p as non-invasive biomarkers in non-small cell lung cancer. *International journal of clinical and experimental pathology*. 11:773-780.

Ben-Dov, I.Z., V.M. Whalen, B. Goilav, K.E. Max, and T. Tuschl. 2016. Cell and Microvesicle Urine microRNA Deep Sequencing Profiles from Healthy Individuals: Observations with Potential Impact on Biomarker Studies. *PloS one*. 11:e0147249.

Bennasar M., H.Y., Setchi R. 2015. Feature Selection Using Joint Mutual Information Maximization. *Expert Systems With Applications*. 42:8520-8532.

Bianchi, F., F. Nicassio, M. Marzi, E. Belloni, V. Dall'olio, L. Bernard, G. Pelosi, P. Maisonneuve, G. Veronesi, and P.P. Di Fiore. 2011. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. *EMBO molecular medicine*. 3:495-503.

Boeri, M., U. Pastorino, and G. Sozzi. 2012. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. *Cancer journal (Sudbury, Mass.)*. 18:268-274.

Boeri, M., C. Verri, D. Conte, L. Roz, P. Modena, F. Facchinetti, E. Calabro, C.M. Croce, U. Pastorino, and G. Sozzi. 2011. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*. 108:3713-3718.

Carbone, D.P., M. Reck, L. Paz-Ares, B. Creelan, L. Horn, M. Steins, E. Felip, M.M. van den Heuvel, T.E. Ciuleanu, F. Badin, N. Ready, T.J.N. Hiltermann, S. Nair, R. Juergens, S. Peters, E. Minenza, J.M. Wrangle, D. Rodriguez-Abreu, H. Borghaei, G.R. Blumenschein, Jr., L.C. Villaruz, L. Havel, J. Krejci, J. Corral Jaime, H. Chang, W.J. Geese, P. Bhagavatheeswaran, A.C. Chen, and M.A. Socinski. 2017. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. *The New England journal of medicine*. 376:2415-2426.

Cazzoli, R., F. Buttitta, M. Di Nicola, S. Malatesta, A. Marchetti, W.N. Rom, and H.I. Pass. 2013. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 8:1156-1162.

Chen, X., Z. Hu, W. Wang, Y. Ba, L. Ma, C. Zhang, C. Wang, Z. Ren, Y. Zhao, S. Wu, R. Zhuang, Y. Zhang, H. Hu, C. Liu, L. Xu, J. Wang, H. Shen, J. Zhang, K. Zen, and C.Y. Zhang. 2012. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. *International journal of cancer*. 130:1620-1628.

Cristescu, R., R. Mogg, M. Ayers, A. Albright, E. Murphy, J. Yearley, X. Sher, X.Q. Liu, H. Lu, M. Nebozhyn, C. Zhang, J.K. Lunceford, A. Joe, J. Cheng, A.L. Webber, N. Ibrahim, E.R. Plimack, P.A. Ott, T.Y. Seiwert, A. Ribas, T.K. McClanahan, J.E. Tomassini, A. Loboda, and D. Kaufman. 2018. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science (New York, N.Y.)*. 362.

Debernardi, S., N.J. Massat, T.P. Radon, A. Sangaralingam, A. Banissi, D.P. Ennis, T. Dowe, C. Chelala, S.P. Pereira, H.M. Kocher, B.D. Young, G. Bond-Smith, R. Hutchins, and T. Crnogorac-Jurcevic. 2015. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. *American journal of cancer research*. 5:3455-3466.

Del Ciello, A., P. Franchi, A. Contegiacomo, G. Cicchetti, L. Bonomo, and A.R. Larici. 2017. Missed lung cancer: when, where, and why? *Diagnostic and interventional radiology (Ankara, Turkey)*. 23:118-126.

Di Leva, G., M. Garofalo, and C.M. Croce. 2014. MicroRNAs in cancer. *Annual review of pathology*. 9:287-314.

Duygu, B., L.J. de Windt, and P.A. da Costa Martins. 2016. Targeting microRNAs in heart failure. *Trends Cardiovasc Med*. 26:99-110.

Ellis, P.M., and R. Vandermeer. 2011. Delays in the diagnosis of lung cancer. *Journal of thoracic disease*. 3:183-188.

Geng, Q., T. Fan, B. Zhang, W. Wang, Y. Xu, and H. Hu. 2014. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer. *Respiratory research*. 15:149.

Gettinger, S.N., J. Choi, N. Mani, M.F. Sanmamed, I. Datar, R. Sowell, V.Y. Du, E. Kaftan, S. Goldberg, W. Dong, D. Zelterman, K. Politi, P. Kavathas, S. Kaech, X. Yu, H. Zhao, J. Schlessinger, R. Lifton, D.L. Rimm, L. Chen, R.S. Herbst, and K.A. Schalper. 2018. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. *Nature communications*. 9:3196.

Han, Y., J. Jiao, and T. Weissman. 2016. Minimax Rate-optimal Estimation of KL Divergence between Discrete Distributions. *Int Symp Inf Theory Appl*. 2016:256-260.

Hayes, J., P.P. Peruzzi, and S. Lawler. 2014. MicroRNAs in cancer: biomarkers, functions and therapy. *Trends in molecular medicine*. 20:460-469.

Jiao, J., K. Venkat, Y. Han, and T. Weissman. 2015. Minimax Estimation of Functionals of Discrete Distributions. *IEEE Trans Inf Theory*. 61:2835-2885.

Kim, D., H.R. Chang, and D. Baek. 2017. Rules for functional microRNA targeting. *BMB Rep*. 50:554-559.

Kozomara, A., and S. Griffiths-Jones. 2014. miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic acids research*. 42:D68-73.

Lackey, A., and J.S. Donington. 2013. Surgical management of lung cancer. *Seminars in interventional radiology*. 30:133-140.

Leidinger, P., C. Backes, M. Blatt, A. Keller, H. Huwer, P. Lepper, R. Bals, and E. Meese. 2014. The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases. *Molecular cancer*. 13:202.

Leidinger, P., T. Brefort, C. Backes, M. Krapp, V. Galata, M. Beier, J. Kohlhaas, H. Huwer, E. Meese, and A. Keller. 2016. High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer. *Oncotarget*. 7:4611-4623.

Li, W., Y. Wang, Q. Zhang, L. Tang, X. Liu, Y. Dai, L. Xiao, S. Huang, L. Chen, Z. Guo, J. Lu, and K. Yuan. 2015. MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer. *PloS one*. 10:e0134220.

Markou, A., M. Zavridou, and E.S. Lianidou. 2016. miRNA-21 as a novel therapeutic target in lung cancer. *Lung Cancer (Auckland, N.Z.)*. 7:19-27.

Nadal, E., A. Truini, A. Nakata, J. Lin, R.M. Reddy, A.C. Chang, N. Ramnath, N. Gotoh, D.G. Beer, and G. Chen. 2015. A Novel Serum 4-microRNA Signature for Lung Cancer Detection. *Scientific reports*. 5:12464.

Nadal, E., J. Zhong, J. Lin, R.M. Reddy, N. Ramnath, M.B. Orringer, A.C. Chang, D.G. Beer, and G. Chen. 2014. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 20:3107-3117.

Polanski, J., B. Jankowska-Polanska, J. Rosinczuk, M. Chabowski, and A. Szymanska-Chabowska. 2016. Quality of life of patients with lung cancer. *OncoTargets and therapy*. 9:1023-1028.

Qu, K., X. Zhang, T. Lin, T. Liu, Z. Wang, S. Liu, L. Zhou, J. Wei, H. Chang, K. Li, Z. Wang, C. Liu, and Z. Wu. 2017. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. *Scientific reports*. 7:1692.

Quinlan, S., A. Kenny, M. Medina, T. Engel, and E.M. Jimenez-Mateos. 2017. MicroRNAs in Neurodegenerative Diseases. *International review of cell and molecular biology*. 334:309-343.

Quint, L.E. 2003. Lung cancer: assessing resectability. *Cancer imaging : the official publication of the International Cancer Imaging Society*. 4:15-18.

Rizvi, N.A., M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J.J. Havel, W. Lee, J. Yuan, P. Wong, T.S. Ho, M.L. Miller, N. Rekhtman, A.L. Moreira, F. Ibrahim, C. Bruggeman, B. Gasmi, R. Zappasodi, Y. Maeda, C. Sander, E.B. Garon, T. Merghoub, J.D. Wolchok, T.N. Schumacher, and T.A. Chan. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science (New York, N.Y.)*. 348:124-128.

Robinson, M.D., D.J. McCarthy, and G.K. Smyth. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics (Oxford, England)*. 26:139-140.

Singh, A., and D. Sen. 2017. MicroRNAs in Parkinson's disease. *Exp Brain Res*. 235:2359-2374.

Socinski, M.A., R.M. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodriguez-Abreu, D. Moro-Sibilot, C.A. Thomas, F. Barlesi, G. Finley, C. Kelsch, A. Lee, S. Coleman, Y.

Deng, Y. Shen, M. Kowanetz, A. Lopez-Chavez, A. Sandler, and M. Reck. 2018. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. *The New England journal of medicine*. 378:2288-2301.

Tyanova, S., and J. Cox. 2018. Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research. *Methods in molecular biology (Clifton, N.J.)*. 1711:133-148.

Wan, N., and J. Zheng. 2021. MicroRNA-891a-5p is a novel biomarker for non-small cell lung cancer and targets HOXA5 to regulate tumor cell biological function. *Oncology letters*. 22:507.

Wang, D., J. Gu, T. Wang, and Z. Ding. 2014. OncomiRDB: a database for the experimentally verified oncogenic and tumor-suppressive microRNAs. *Bioinformatics (Oxford, England)*. 30:2237-2238.

Wojciechowska, A., A. Braniewska, and K. Kozar-Kaminska. 2017. MicroRNA in cardiovascular biology and disease. *Advances in clinical and experimental medicine : official organ Wroclaw Medical University*. 26:865-874.

Wozniak, M.B., G. Scelo, D.C. Muller, A. Mukeria, D. Zaridze, and P. Brennan. 2015. Circulating MicroRNAs as Non-Invasive Biomarkers for Early Detection of Non-Small-Cell Lung Cancer. *PloS one*. 10:e0125026.

Yan, G., R. Yao, D. Tang, T. Qiu, Y. Shen, W. Jiao, N. Ge, Y. Xuan, and Y. Wang. 2014. Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib. *Medical oncology (Northwood, London, England)*. 31:203.

Zhou, X., W. Wen, X. Shan, W. Zhu, J. Xu, R. Guo, W. Cheng, F. Wang, L.W. Qi, Y. Chen, Z. Huang, T. Wang, D. Zhu, P. Liu, and Y. Shu. 2017. A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis. *Oncotarget*. 8:6513-6525.

Zhu, W., K. Zhou, Y. Zha, D. Chen, J. He, H. Ma, X. Liu, H. Le, and Y. Zhang. 2016. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer. *PloS one*. 11:e0153046.